Quick Answer
IDEAYA Biosciences, Inc. reported Cash and Equivalents of $112.83 million for fiscal year 2025.
IDEAYA Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $112.83M | +33.7% |
| 2024 | $84.38M | -46.3% |
| 2023 | $157.02M | +128.8% |
| 2022 | $68.63M | -25.4% |
| 2021 | $92.05M | +27.8% |
| 2020 | $72.04M | +111.5% |
| 2019 | $34.07M | +66.1% |
| 2018 | $20.50M | +244.0% |
| 2017 | $5.96M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $298.93M | -25.3% | +160.7% |
| June 30, 2025 | $114.64M | -37.4% | -11.8% |
| March 31, 2025 | $130.00M | +20.0% | +54.1% |
| December 31, 2024 | $84.38M | -46.3% | -78.9% |
| September 30, 2024 | $400.28M | +163.6% | +118.7% |
| June 30, 2024 | $183.05M | +78.0% | +69.0% |
| March 31, 2024 | $108.34M | +61.1% | -31.0% |
| December 31, 2023 | $157.02M | +128.8% | +3.4% |
- IDEAYA Biosciences, Inc. showed an increase of +33.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2025 period, IDEAYA Biosciences, Inc.’s cash and equivalents has grown by 1792.7% (from $5.96 million to $112.83 million).
- The most recent figure is from IDEAYA Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: